Pfizer (PFE) Stock
Global pharmaceutical company producing medicines and vaccines. Here's the price, business snapshot, and what's worth knowing about Pfizer in August 2026.
Pfizer Inc (PFE) is a large-cap global pharmaceutical company known for developing, producing and commercialising medicines and vaccines across areas such as oncology, immunology, rare disease and infectious disease. The company’s scale, diversified portfolio and R&D pipeline are key considerations for investors: revenue is driven by established products, new approvals and licensing or royalty arrangements. Important risks include regulatory decisions, patent expiries, pricing pressure, competition and litigation — all of which can materially affect earnings. Pfizer has historically returned capital to shareholders via dividends and buybacks, but dividend levels and capital allocation depend on cash flow and strategic priorities. For those researching the stock, focus on upcoming clinical readouts, regulatory milestones, patent timelines, and quarterly financials. This is general educational information, not personal advice; pharmaceutical stocks can be volatile and past performance is not a reliable indicator of future results.
Why It’s Moving
Pfizer is still moving on earnings momentum, but legal risk is keeping gains in check.
- Pfizer’s Aug. 4 earnings beat expectations and the company raised the midpoint of its 2026 revenue outlook, easing some worries about post-COVID growth and showing its non-COVID portfolio is doing more of the heavy lifting.
- Investors also reacted to stronger sales from acquired and recently launched medicines, which reinforced the view that Pfizer’s turnaround depends on pipeline execution rather than pandemic-era products.
- A fresh legal overhang around Depo Provera lawsuits has added some caution, reminding traders that litigation risk can still weigh on sentiment even after a solid quarter.
Pfizer is still moving on earnings momentum, but legal risk is keeping gains in check.
- Pfizer’s Aug. 4 earnings beat expectations and the company raised the midpoint of its 2026 revenue outlook, easing some worries about post-COVID growth and showing its non-COVID portfolio is doing more of the heavy lifting.
- Investors also reacted to stronger sales from acquired and recently launched medicines, which reinforced the view that Pfizer’s turnaround depends on pipeline execution rather than pandemic-era products.
- A fresh legal overhang around Depo Provera lawsuits has added some caution, reminding traders that litigation risk can still weigh on sentiment even after a solid quarter.
Sixth Month Growth Performance
next-earnings-question
Pfizer’s next earnings date is expected to be November 3, 2026, based on the company’s usual reporting pattern. The upcoming release should cover Q3 2026 results. If the company confirms a final date, it would typically be within the same early-November window.
Stock Performance Snapshot
Analyst Rating
Analysts suggest holding Pfizer's stock, expecting it to rise slightly in value.
Financial Health
Pfizer is generating strong revenue and profits, showing good cash flow and healthy margins.
Dividend
Pfizer's high dividend yield of 6.46% is appealing for those seeking dividend income. If you invested $1000, you would be paid $64.60 a year in dividends (based on the last 12 months).
Why You’ll Want to Watch This Stock
Pipeline and innovation
Clinical readouts and regulatory approvals can shift expectations quickly, so investors often watch the pipeline closely — though outcomes can be uncertain.
Key revenue drivers
Vaccines, blockbusters and royalty agreements drive sales, but patent cliffs and pricing pressures can affect future revenue.
Global market reach
Pfizer operates worldwide with diverse market exposure, which can smooth regional volatility but also creates regulatory and geopolitical risks.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
